In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...